Mersana Therapeutics Inc
NASDAQ:MRSN

Watchlist Manager
Mersana Therapeutics Inc Logo
Mersana Therapeutics Inc
NASDAQ:MRSN
Watchlist
Price: 29.08 USD 0.14%
Market Cap: 145.4m USD

Mersana Therapeutics Inc
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Mersana Therapeutics Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Mersana Therapeutics Inc
NASDAQ:MRSN
Operating Income
-$67.4m
CAGR 3-Years
31%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Operating Income
$19.7B
CAGR 3-Years
0%
CAGR 5-Years
9%
CAGR 10-Years
13%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$11.3B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Operating Income
$12.1B
CAGR 3-Years
6%
CAGR 5-Years
6%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.5B
CAGR 3-Years
2%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$3.9B
CAGR 3-Years
-17%
CAGR 5-Years
4%
CAGR 10-Years
12%
No Stocks Found

Mersana Therapeutics Inc
Glance View

Market Cap
145.4m USD
Industry
Biotechnology

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing antibody drug conjugates that offer clinical benefit for cancer patients with significant unmet need. The company is headquartered in Cambridge, Massachusetts and currently employs 169 full-time employees. The company went IPO on 2017-06-28. The firm is focused on developing antibody drug conjugates (ADCs). The Company’s platforms include Dolaflexin and Dolasynthen. Its product candidates include upifitamab rilsodotin (UpRi, XMT-1536) and XMT-1592. The Company’s early stage programs include B7-H4-targeted Dolasynthen ADC, XMT-1660, as well as candidates leveraging the Immunosynthen platform. UpRi is an ADC utilizing the Company’s Dolaflexin platform and targeting NaPi2b, which is an antigen broadly expressed in ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma. XMT-1592 uses the Company’s Dolasynthen platform and targets NaPi2b.

MRSN Intrinsic Value
10.94 USD
Overvaluation 62%
Intrinsic Value
Price

See Also

What is Mersana Therapeutics Inc's Operating Income?
Operating Income
-67.4m USD

Based on the financial report for Sep 30, 2025, Mersana Therapeutics Inc's Operating Income amounts to -67.4m USD.

What is Mersana Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 5Y
2%

Over the last year, the Operating Income growth was 15%. The average annual Operating Income growth rates for Mersana Therapeutics Inc have been 31% over the past three years , 2% over the past five years .

Back to Top